1. The role of plasma transforming growth factor beta-1 in the development of fibrosis in patient with HCV related steatohepatitis
- Author
-
Gamal M M, Soliman, Khairy Abd El Hameed, Mohammed, Ashraf, Taha, and Abd-Almonim M, Barrak
- Subjects
Adult ,Fatty Liver ,Liver Cirrhosis ,Male ,Transforming Growth Factor beta1 ,Young Adult ,Humans ,Female ,Hepacivirus ,Middle Aged ,Hepatitis C - Abstract
Hepatitis C virus (HCV) is a major public health problem worldwide, which causes high rate of chronic liver disease such as liver cirrhosis and hepatocellular carcinoma. Plasma transforming growth factor Beta-1 (TGFB-1) is a member of large family of peptides, which has a major regulatory role in hepatic fibrosis and cirrhosis. The study evaluated the role of transforming growth factor Beta-1 (TGFB-1) in induction of fibrosis in liver parasites-free HCV patients with related steatohepatitis. Thirty HCV patients who were clinically and serologically positive were selected. They were diagnosed as fatty liver by abdominal ultrasonography; steatohepatitis and confirmed by histopathological biopsies examination. ELISA evaluated plasma transforming growth factor Beta-1 (TGFB-1) level. Also, 12 cross-matched subjects clinically, parasitologically and serologically free were used as a controls. The level of plasma transforming growth factor Beta-1 (TGFB-1) was highly elevated in the patients versus controls with mean +/- SD 18739.86 +/- 18539.46 and 6465 +/- 1142 respectively (P0.001). The TGFB-1 level in HCV related steato-hepatitis was elevated in all grades in contrast to controls (P0.05), without relation between the TGFB-1 levels and steatohepatitis severity. The TGFB-1 level showed high significant difference in all stages of fibrosis in patients in contrast to controls and the TGFB-1 level was very high when fibrosis started in stage I (P0.01) and tended to decrease in fibrosis of stage 23 (P0.05). There was highly significant positive correlation between TGFB-1 and body mass index (BMI) r = 0.774.
- Published
- 2011